Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this latest episode of the VJOncoAlert Journal Club, Erika Hamilton, MD, Sarah Cannon Cancer Center, Nashville, TN, discusses the findings of the VERITAC-2 trial (NCT05654623), a Phase III, open-labeled, randomized trial evaluating vepdegestrant, an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, in patients with ER-positive, HER2-negative advanced breast cancer, as published in the New England Journal of Medicine (NEJM). In the VERITAC-2 trial, vepdegestrant significantly improved progression-free survival versus fulvestrant in ESR1-mutated advanced breast cancer patients previously treated with endocrine therapy and CDK4/6 inhibitors.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next